APIBAX (Nova Pharmaceuticals Australasia Pty Ltd)
Product name
APIBAX
Date registered
Evaluation commenced
Decision date
Approval time
133 (255 working days)
Active ingredients
Apixaban
Registration type
New generic medicine
Indication
APIBAX is indicated for the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip or total knee replacement surgery.
APIBAX is indicated for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke.
APIBAX is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adult patients.
APIBAX is indicated for the prevention of recurrent DVT and PE in adult patients.